July 15, 2021

Episode 183: 183. PART 2 DYSH Out Information on DYSlipidemia, an Evidence Based Approach

16 minutes

DYSh out information on DYSlipidemia: An Evidence-based Update on Cholesterol Management

Please contact me for more information: Andrew Buelt, D.O.

[email protected]

Questioning Medicine Podcast

Athrosclerotic Cardiovascular Disease Risk Calculator (ASCVD)

10 yr ASCVD risk calculator developed in 2013

ASCVD event defined as nonfatal myocardial infarction, coronary heart disease (CHD) death, fatal or nonfatal stroke

Development of ASCVD calculator used African-American and White men and women age 40 to 79 yrs old (not hispanic, watch for inclusion drift)

Risk assessment should occur every 5 yrs in moderate risk individuals and can occur more frequently if the patient is nearing a cutoff for treatment

Serum Lipid Level

Lipid levels are stable over long durations of time

Serum lipid lab values have high intra-test variability

Testing more frequently than every 10 years leads to overdiagnosis from lab error and not true changes in serum lipid levels.

Primary Prevention

Treatment

Statins are the only currently approved drug to reduce cardiovascular events in primary prevention patients

Primary prevention statins should be used for those with diabetes, LDL ≥ 190, ASCVD 10 yr risk of 11.25%

No trial has EVER looked at treatment titration to a specific cholesterol number compared to standard treatment dose...EVER

Coronary Calcium Scoring

No prospective RCT exist

Largest observational study currently in existence had 5,185 patients, 58 patients were correctly reclassified, 292 patients incorrectly reclassified, 4,835 patients had no benefit or harm other than lost time, money, resources (0.3% benefit, 6.7% harm, 93% no benefit or harm)

Secondary Prevention

Define as individuals with previous angina, MI with or without intervention, ischemic stroke/TIA, peripheral arterial disease (claudication or abdominal aortic aneurysm)

Treatment

-First Line Treatment = Statin

High dose statin reduces major adverse cardiovascular events by 1% more than moderate dose statin

High dose statin cause adverse events WITH therapy discontinuation 1% more often moderate dose statin

ANY dose statin is better than no statin

Statins cause myalgias at a rate that is not statistically different from placebo

Second line treatment

Increase statin dose to max tolerated then add Ezetimibe

Third line treatment

PCSK9 inhibitor

...more

View all episodes

By Questioning Medicine

4.9

7474 ratings